Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults - PubMed (original) (raw)
Clinical Trial
doi: 10.1159/000023319.
Affiliations
- PMID: 10352397
- DOI: 10.1159/000023319
Clinical Trial
Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults
K R Kim et al. Horm Res. 1999.
Abstract
Growth hormone (GH) can induce an accelerated lipolysis. Impaired secretion of GH in obesity results in the consequent loss of the lipolytic effect of GH. Dietary restriction as a basic treatment for obesity is complicated by poor compliance, protein catabolism, and slow rates or weight loss. GH has an anabolic effect by increasing insulin-like growth factor (IGF)-I. We investigated the effects of GH treatment and dietary restriction on lipolytic and anabolic actions, as well as the consequent changes in insulin and GH secretion in obesity. 24 obese subjects (22 women and 2 men; 22-46 years old) were fed a diet of 25 kcal/kg ideal body weight (IBW) with 1.2 g protein/kg IBW daily and were treated with recombinant human GH (n = 12, 0.18 U/kg IBW/week) or placebo (n = 12, vehicle injection) in a 12-week randomized, double-blind and placebo-controlled trial. GH treatment caused a 1.6-fold increase in the fraction of body weight lost as fat and a greater loss of visceral fat area than placebo treatment (35.3 vs. 28.5%, p < 0.05). In the placebo group, there was a loss in lean body mass (-2.62 +/- 1.51 kg) and a negative nitrogen balance (-4.52 +/- 3.51 g/day). By contrast, the GH group increased in lean body mass (1.13 +/- 1.04 kg) and had a positive nitrogen balance (1.81 +/- 2.06 g/day). GH injections caused a 1.6-fold increase in IGF-I, despite caloric restriction. GH response to L-dopa stimulation was blunted in all subjects and it was increased after treatment in both groups. GH treatment did not induce a further increase in insulin levels during an oral glucose tolerance test (OGTT) but significantly decreased free fatty acid (FFA) levels during OGTT. The decrease in FFA area under the curve during OGTT was positively correlated with visceral fat loss. This study demonstrates that in obese subjects given a hypocaloric diet, GH accelerates body fat loss, exerts anabolic effects and improves GH secretion. These findings suggest a possible therapeutic role of low-dose GH with caloric restriction for obesity.
Similar articles
- Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY, Kim KR, Cha BS, Song YD, Lim SK, Lee HC, Huh KB. Nam SY, et al. Int J Obes Relat Metab Disord. 2001 Aug;25(8):1101-7. doi: 10.1038/sj.ijo.0801636. Int J Obes Relat Metab Disord. 2001. PMID: 11477493 Clinical Trial. - Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition.
Snyder DK, Clemmons DR, Underwood LE. Snyder DK, et al. J Clin Endocrinol Metab. 1988 Jul;67(1):54-61. doi: 10.1210/jcem-67-1-54. J Clin Endocrinol Metab. 1988. PMID: 3379136 - Growth hormone administration conserves lean body mass during dietary restriction in obese subjects.
Clemmons DR, Snyder DK, Williams R, Underwood LE. Clemmons DR, et al. J Clin Endocrinol Metab. 1987 May;64(5):878-83. doi: 10.1210/jcem-64-5-878. J Clin Endocrinol Metab. 1987. PMID: 3558728 - Growth hormone in obesity.
Scacchi M, Pincelli AI, Cavagnini F. Scacchi M, et al. Int J Obes Relat Metab Disord. 1999 Mar;23(3):260-71. doi: 10.1038/sj.ijo.0800807. Int J Obes Relat Metab Disord. 1999. PMID: 10193871 Review. - Obesity, growth hormone and weight loss.
Rasmussen MH. Rasmussen MH. Mol Cell Endocrinol. 2010 Mar 25;316(2):147-53. doi: 10.1016/j.mce.2009.08.017. Epub 2009 Aug 31. Mol Cell Endocrinol. 2010. PMID: 19723558 Review.
Cited by
- Obesity and Cardiovascular Risk: Systematic Intervention Is the Key for Prevention.
Perone F, Pingitore A, Conte E, Halasz G, Ambrosetti M, Peruzzi M, Cavarretta E. Perone F, et al. Healthcare (Basel). 2023 Mar 21;11(6):902. doi: 10.3390/healthcare11060902. Healthcare (Basel). 2023. PMID: 36981559 Free PMC article. Review. - Growth Hormone's Effect on Adipose Tissue: Quality versus Quantity.
Berryman DE, List EO. Berryman DE, et al. Int J Mol Sci. 2017 Jul 26;18(8):1621. doi: 10.3390/ijms18081621. Int J Mol Sci. 2017. PMID: 28933734 Free PMC article. Review. - Growth hormone-releasing hormone is produced by adipocytes and regulates lipolysis through growth hormone receptor.
Rodríguez-Pacheco F, Gutierrez-Repiso C, García-Serrano S, Ho-Plagaro A, Gómez-Zumaquero JM, Valdes S, Gonzalo M, Rivas-Becerra J, Montiel-Casado C, Rojo-Martínez G, García-Escobar E, García-Fuentes E. Rodríguez-Pacheco F, et al. Int J Obes (Lond). 2017 Oct;41(10):1547-1555. doi: 10.1038/ijo.2017.145. Epub 2017 Jun 19. Int J Obes (Lond). 2017. PMID: 28626214 - Obesity, growth hormone and exercise.
Thomas GA, Kraemer WJ, Comstock BA, Dunn-Lewis C, Maresh CM, Volek JS. Thomas GA, et al. Sports Med. 2013 Sep;43(9):839-49. doi: 10.1007/s40279-013-0064-7. Sports Med. 2013. PMID: 23812873 Review. - The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations.
Berryman DE, Glad CA, List EO, Johannsson G. Berryman DE, et al. Nat Rev Endocrinol. 2013 Jun;9(6):346-56. doi: 10.1038/nrendo.2013.64. Epub 2013 Apr 9. Nat Rev Endocrinol. 2013. PMID: 23568441 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical